Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Gossamer Bio Announces Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting


Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that GB1275, the Company's oral CD11b modulator for oncology indications, will be featured in a trial-in-progress poster at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, being held November 6-10 in National Harbor, Maryland. The poster will highlight the Company's ongoing first-in-human Phase 1/2 trial of GB1275 as a monotherapy and in combination with anti-PD-1 therapy in certain advanced solid tumors known to be immuno-oncology resistant, and with standard of care chemotherapy in metastatic pancreatic cancer.

Details for the SITC presentation is as follows:

Title: A phase 1/2 study of GB1275, a novel CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (mPDAC)
Presenter: Jakob Dupont, MD, Chief Medical Officer, Gossamer Bio
Poster Number: P419
Location: Prince George's Exhibition Halls AB
Date/Time: November 8, 2019, 12:30-2:00 p.m. and 6:30-8:00 p.m. ET

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.


These press releases may also interest you

at 20:50
Overture Launches Inner Circles: Redefining Private Attorney Referral Networks
Overture.law, the nation's leading attorney-to-attorney referral platform, launches their transformative new product, Inner Circles. This groundbreaking product empowers attorneys, law schools, bar associations, and affinity groups to build private...

at 20:09
Not Just 1, But 2: BASIS Charter Schools Celebrates a Pair of Students Named Presidential Scholars by the U.S. Department of Education
BASIS Charter Schools proudly announce that two of its exceptional students have been named 2024 U.S. Presidential Scholars by the U.S. Department of Education. Matteo N. Huish from BASIS Mesa and Sruti Peddi from BASIS Scottsdale have been...

at 20:00
Greenberg Traurigs Kemal Hawa to Moderate Panel at DICE East 2024
Kemal Hawa, co-chair of the Digital Infrastructure, Data Center and Cloud Computing Practice of global law firm Greenberg Traurig, LLP, will moderate a panel at DICE East 2024 May 22 in Reston, Virginia. Hawa, a member of the firm's Washington,...

at 19:45
WIO Taps Gracenote to Revolutionize Television Broadcast Reporting
WIO LLC, parent company of the global TV broadcast airings platform, WIOprotm, has announced a new strategic agreement with Gracenote, the global content data business unit of Nielsen, to address the longstanding challenge of accurately tracking and...

at 19:35
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

More news about Science and technology...


News published on and distributed by: